Trending Up0.0350 (1.5419%)
  • Bid / Lots
    2.3000/ 8
  • Ask / Lots
    2.3100/ 6
  • Open / Previous Close
    2.2700 / 2.2700
  • Day Range
    Low 2.2700
    High 2.3500
  • 52 Week Range
    Low 1.6000
    High 7.7300
  • Volume
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 2.27
09:32 ET4482.29
09:34 ET3002.31
09:36 ET1002.3
09:38 ET5002.3
09:39 ET16082.32
09:41 ET19182.345
09:43 ET3002.34
09:45 ET26002.34
09:48 ET5002.345
09:50 ET1002.34
09:52 ET11002.33
09:54 ET28612.315
09:59 ET4002.2998
10:01 ET8002.3
10:03 ET2002.295
10:10 ET24642.285
10:12 ET2002.285
10:17 ET1002.28
10:24 ET7002.29
10:26 ET1002.3
10:32 ET1002.305
10:33 ET1002.325
10:35 ET6002.32
10:39 ET1002.32
10:46 ET1002.33
10:50 ET1002.335
10:51 ET1002.335
11:00 ET7002.34
11:02 ET4002.345
11:04 ET2762.34
11:18 ET11002.345
11:20 ET51902.35
11:29 ET8752.3401
11:38 ET1002.345
11:44 ET27002.33
11:49 ET1002.315
11:51 ET1002.32
11:58 ET48882.32
12:05 ET3002.32
12:07 ET23872.305
12:09 ET1002.305
12:14 ET2002.29
12:18 ET1002.29
12:20 ET1002.28
12:21 ET10002.29
12:27 ET2002.29
12:30 ET3922.285
12:32 ET10472.29
12:36 ET1002.3
12:41 ET1002.29
12:45 ET6172.2941
12:52 ET1002.2987
12:54 ET1002.295
12:56 ET5002.3
12:59 ET1002.305
01:01 ET1002.305
01:08 ET1002.305
01:14 ET5002.305
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesPBYI
Puma Biotechnology Inc
United StatesOVID
Ovid Therapeutics Inc
United StatesAKBA
Akebia Therapeutics Inc
United StatesMDXG
MiMedx Group Inc
United StatesCNTG
Centogene NV
United StatesKPTI
Karyopharm Therapeutics Inc
As of 2022-09-27

Company Information

Puma Biotechnology, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of products to enhance cancer care. The Company's lead product is NERLYNX, an oral version of neratinib, which is a potent irreversible tyrosine kinase inhibitor (TKI) that blocks signal transduction through the human epidermal growth factor receptors, HER1, HER2 and HER4. It is primarily focused on the development and commercialization of the oral version of neratinib, and its advanced drug candidates are directed at the treatment of HER2-positive breast cancer and HER2 mutated cancers. Its other products include PB272 (neratinib, intravenous), PB357, and certain related compounds. Its neratinib has clinical application in the treatment of several other cancers as well, including other tumor types that over-express or have a mutation in HER2 or epidermal growth factor receptor (EGFR), such as breast cancer, cervical cancer, lung cancer, or other solid tumors.

Contact Information

SUITE 2150, 10880 WILSHIRE BLVD.LOS ANGELES, CA, United States 90024


Chairman of the Board, President, Chief Executive Officer, Secretary
Alan Auerbach
Chief Financial Officer
Maximo Nougues
Senior Vice President - Regulatory Affairs, Medical Writing and Project Management
Douglas Hunt
Chief Scientific Officer
Alvin Wong
Chief Commercial Officer
Jeff Ludwig

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
Revenue (TTM)
Shares Outstanding
Dividend Yield
Annual Dividend Rate
Ex-Dividend Date
Pay Date
Book Value
P/E Ratio
Price/Sales (TTM)
Price/Cash Flow (TTM)
Operating Margin
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.